BACKGROUND: Women with refractory urgency urinary incontinence (ie, unresponsive to behavioral and pharmacological interventions) are treated with onabotulinumtoxinA or sacral neuromodulation. OBJECTIVE: The objective of the study was to compare treatment efficacy and adverse events in women <65 and !65 years old treated with onabotulinumtoxinA or sacral neuromodulation. STUDY DESIGN: This study was a planned secondary analysis of a multicenter, randomized trial that enrolled community-dwelling women with refractory urgency urinary incontinence to onabotulinumtoxinA or sacral neuromodulation treatments. The primary outcome was a change in mean daily urgency urinary incontinence episodes on a bladder diary over 6 months. Secondary outcomes included !75% urgency urinary incontinence episode reduction, change in symptom severity/quality of life, treatment satisfaction, and treatment-related adverse events. RESULTS: Both age groups experienced improvement in mean urgency urinary incontinence episodes per day following each treatment. There was no evidence that mean daily urgency urinary incontinence episode reduction differed between age groups for onabotulinumtoxinA (adjusted coefficient, e0.127, 95% confidence interval, e1.233 to 0.979; P ¼ .821) or sacral neuromodulation (adjusted coefficient, e0.698, 95%
U rgency urinary incontinence (UUI) is characterized by involuntary urinary leakage that occurs with a sudden, compelling desire to void that is difficult to defer. Refractory UUI is defined as UUI that has not responded to behavioral therapies with lack of response or intolerance to at least 2 medications.
1 UUI prevalence increases with age, 2 and its attendant consequences, including diminished social interaction, increased fall-related injury and reduced quality of life, profoundly affects older women. 1, 3 Studies of refractory UUI treatments have demonstrated efficacy of both onabotulinumtoxinA and sacral neuromodulation (SNM). 1, 4, 5 However, efficacy and safety data for these treatments in the older population are limited. Older patients have been underrepresented in clinical research because of exclusion and underrecruitment, likely because of concerns regarding participants' multiple comorbidities and risk of adverse events. 6 It is important to evaluate treatment effects and complications associated with onabotulinumtoxinA and SNM in older women because age bias has hampered the study of outcomes in this population.
The Refractory Overactive Bladder: Sacral Neuromodulation vs Botulinum Toxin Assessment (ROSETTA) study is a 9-center, open-label, randomized trial involving 381 community-dwelling women with idiopathic refractory UUI randomized to onabotulinumtoxinA or sacral neuromodulation. 7 Its 6 month results have been published. 7 The trial intentionally included older women and stratified participants by age and treatment, allowing for a more detailed evaluation of the impact of age on refractory UUI treatments.
The objective of this planned secondary analysis was to compare symptom control and adverse events (AEs) over the first 6 months following refractory UUI treatment in women <65 years compared with women !65 years.
Materials and Methods Design
The design and primary results of the randomized trial comparing 6 month outcomes have been published. 7 The current comparative cohort study evaluated age-related treatment efficacy and complications relative to these treatments. Original Research ajog.org
Participants and Procedures
Women were recruited from 9 sites participating in the National Institutes of healthesponsored Pelvic Floor Disorders Network and were stratified by age into women <65 vs !65 years, the typical age for Medicare eligibility. Inclusion criteria for participants included women with persistent UUI symptoms despite undergoing at least 1 supervised behavioral or physical therapy intervention and use of !2 incontinence medications (or inability to tolerate or contraindications to the medications). Participants were required to have a minimum of 6 UUI episodes on a baseline 3 day bladder diary. Participants had stopped UUI medications for a minimum of 3 weeks prior to baseline evaluation and had urodynamic assessment within 18 months prior to randomization. Women with relevant neurological diseases, elevated postvoid residuals, or a history of using either onabotulinumtoxinA or SNM were excluded. All sites received local institutional review board approval (UNMH IRB #11-423).
After obtaining written consent, standardized demographic and clinical data and key procedural elements were collected. Medical comorbidities were assessed with the Functional Comorbidity Index (FCI) questionnaire. 8 All participants were instructed on selfcatheterization, and participants or identified personnel were required to demonstrate the ability to perform catheterization. Definitions of clinical terms, methods of evaluation, and procedural elements were standardized across sites as described previously. 7 
Interventions
Participants were randomized 1:1 to onabotulinumtoxinA or SNM stratified by clinical site and age group (<65 vs >65 years). The random allocation sequence was concealed to all, other than a single data coordinating center statistician. 7 SNM participants underwent a firststage lead placement by experienced surgeons in the operating suite. During the 7e14 day testing phase, participants with !50% improvement in mean UUI episodes (UUIEs) on a 3 day bladder diary were categorized a priori as clinical responders and were eligible for placement of the permanent implantable pulse generator. A !50% reduction in UUIE from baseline is the threshold used in clinical practice to proceed with pulse generator implantation based on Food and Drug Administration recommendations. Those without this improvement underwent lead removal.
Participants randomized to onabotulinumtoxinA received a cystoscopic intradetrusor injection of 200 U of onabotulinumtoxinA performed in the clinic. Women with !50% reduction in UUIEs on a bladder diary 1 month after the injection were a priori defined as clinical responders and were eligible for future injections as specified by the study protocol. 7 After injection, onabotulinumtoxinA participants were followed up for urinary retention and those with a postvoid residual >300 mL or >200 mL with symptoms of incomplete voiding were instructed to perform clean intermittent catheterization after treatment.
Outcomes and data collection
The primary treatment outcome for the current study was change from baseline in mean number of daily UUIEs averaged over 6 months, as recorded for 3 days on monthly bladder diaries. Other outcomes included the proportion of subjects with !75% reduction in daily UUIEs through 6 months and questionnaire results.
Quality of life and symptom severity were assessed monthly with the Overactive Bladder Questionnaire Short Form (OABq-SF). 9 Other measures assessed at baseline and 6 months included the Sandvik questionnaire, 10 a measure of incontinence severity, the Urinary Distress Inventory Short Form, 11 the Incontinence Impact Questionnaire (IIQ) Short Form, 11 the Health Utility Index Mark-3 (HUI-3), 12 and the Life Space Assessment (LSA), 13 a measure of participants' mobility patterns. The Patient Global Impression of Improvement 14 and the Overactive Bladder Satisfaction of Treatment (OAB-SATq) 15 were measured only at 6 months. OAB-SATq subcategories measure treatment satisfaction, adverse effects, treatment endorsement, and convenience.
Safety and AE secondary outcomes were collected monthly, including the proportion of onabotulinumtoxinA participants with urinary retention requiring catheterization at 2 weeks and 1, 3, and 6 months. Additional information was collected regarding the proportion of SNM participants requiring surgical revisions because of surgical site infection, pain, or lead migration and the proportion in each group receiving urinary tract infection (UTI) treatment, either culture positive and/or because of symptoms.
Statistical analysis
The analysis of reduction in mean UUIE utilized a modified intention to treat a population that included all eligible participants who provided at least 1 postbaseline bladder diary assessment. The analysis of those participants who achieved !75% reduction in UUIEs on each available bladder diary was limited to participants with a minimum of 4 months of completed diaries. The analysis of quality-of-life measures was based on the full intention to treat the population who had at least 1 postbaseline measure on the outcome measure. The safety and AE analysis was based on the full intention-to-treat population.
Analyses of reduction in mean UUIE used a multivariable linear mixed model with participant-month in the study (1e6) as the unit of analysis and reduction from baseline in mean UUIE per day from the monthly diary as the outcome, with terms for treatment group, month, age group, interaction of treatment group with month, interaction of treatment group with age group, and site.
Participant was treated as a random effect to account for within-person correlation in diary outcomes over time. Additional candidate covariates considered for inclusion were race, body mass index, FCI, diabetes (types 1 and 2), degenerative disc disease, daily UUIE, IIQ, Sandvik severity score, HUI-3, and smoking, with only those covariates found to be associated with the outcome at P < .10 included in the multivariable model; in building the multivariable Original Research GYNECOLOGY ajog.org model, candidate covariates were removed in a stepwise fashion (largest P value first) to achieve a final model that included covariates with P < .10.
Analysis for discrete outcome of !75% reduction in UUIEs used an analogous process with a multivariable logistic regression model. Effect sizes and confidence intervals were generated using appropriate linear combinations of the model coefficient estimates. Analysis of continuous measures of quality of life and efficacy, such as change in OAB symptom bother or change in HUI, used the same linear mixed model described in previous text but without consideration of covariates beyond the treatment group, age group, month, and site. Aggregate binary measures were evaluated using contingency tables, with the differences between treatment groups assessed with the MantelHaenszel tests accounting for randomization strata.
The study was designed to conduct formal analyses for only the primary outcome at the P ¼ .05 level of significance, and all other results and P values are considered descriptive. Consequently, no adjustments have been made for multiple comparisons. Analyses were performed with the use of SAS software, version 9.3 (SAS Institute, Cary, NC). All inferences and descriptive P values are based on 2-sided tests.
Results

Study population
Three hundred sixty-four women with refractory UUI were followed up for 6 months following randomization to intravesical onabotulinumtoxinA or SNM and were stratified by age as <65 years old (n ¼ 191) and !65 years (n ¼ 173). Participant baseline characteristics are listed in Table 1 . Younger women had a higher mean body mass index, were more often nonwhite, and were more often smokers. Older women had higher mean FCI (ie, more comoribidities), better (higher) mean OABq quality of life, and better (lower) mean IIQ scores. In subjects <65 years old, 100 were treated with onabotulinumtoxinA and 91 with SNM; in women !65 years old, 90 were treated with onabotulinumtoxinA and 83 with SNM (Table 2) .
Incontinence outcomes
There was no evidence of a difference in mean daily reduction of UUIE between younger and older women within either the onabotulinumtoxinA (P ¼ .821) or SNM (P ¼ .227) groups (Table 2) . Variables independently associated with UUIE reduction over 6 months included baseline HUI-3 scores and baseline daily mean number of UUIE. Higher (ie, better) HUI-3 scores predicted greater reduction of mean UUIE for younger but not older women; for each 0.3 increase in HUI-3 score, there was a mean reduction of 0.54 UUIE/day. Higher baseline UUIE/ day predicted greater reduction for both younger and older women with a mean reduction of 0.62 UUIE/day following treatment.
Younger women had a 3.3 times greater odds of attaining !75% resolution of UUIE than women !65 years old (95% confidence interval [CI], 1.56e7.02) in the 6 months following onabotulinumtoxinA treatment (Table 3 ). In women undergoing SNM, there was no evidence of an age difference (P ¼ .72). In addition to age, variables associated with !75% UUIE reduction included the presence of degenerative disc disease and IIQ and Sandvik severity scores.
The presence of degenerative disc disease decreased the odds of achieving !75% UUIE reduction in women treated with onabotulinumtoxinA (adjusted odds ratio [aOR], 0.15, 95% CI, 0.06e0.39). This effect was not observed in women treated with SNM, nor did this variable differentially affect older vs younger women. A similar pattern was observed for IIQ score, in which higher (ie, worse) baseline scores predicted a lower odds of !75% resolution in women treated with onabotulinumtoxinA but not in women treated with SNM. Higher (ie, worse) Sandvik severity scores at baseline decreased the odds of !75% UUIE reduction for both older and younger women treated with either treatment.
Symptom-specific quality-of-life outcomes Improvements in OAB symptom bother and satisfaction scores in women <65 years were greater than women !65 years with no evidence of a difference between treatment groups (Appendix). OAB-satisfaction endorsement and convenience scores reflected better outcomes in women <65 years treated with onabotulinumtoxinA; scores in women undergoing SNM did not differ by age. LSA scores worsened in women <65 years treated with onabotulinumtoxinA, but there was no evidence of differences between age groups in women treated with SNM.
Older women more commonly had UTIs following both onabotulinumtoxinA and SNM treatments (an approximate 2-fold increase; Appendix), and a similar trend (Appendix) in older women occurred regarding recurrent UTIs, although this did not reach statistical significance.
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This planned secondary analysis of data obtained from women with refractory UUI undergoing treatment with onabotulinumtoxinA or SNM is particularly important for older women because significant changes in the lower urinary tract may accompany aging. These changes include decreased detrusor contractility and decreased urethral vascular density and pressure, 16, 17 which may affect micturition efficiency and continence and could have a differential impact on both chemical and electrical neuromodulation treatment modalities.
In this study, older women differed from younger women with respect to ajog.org Original Research GYNECOLOGY ajog.org several baseline variables. Although statistically significant, it is unclear whether all these were clinically significant. For example, the difference in FCI scores between groups did not meet a conservative estimate of a minimal clinically important difference of half the standard deviation. 18 The IIQ score, however, exceeded the minimally important difference 19 This suggests that these older women, despite similar distress and symptom severity scores, had less clinical impact at baseline (ie, had better IIQ scores) than younger women. Perhaps this represents age or generational differences in symptom perception and suggests improved adaptation to the impact of incontinence by these older women. With respect to posttreatment incontinence outcomes, there was no difference in mean daily UUIE reduction over 6 months in younger compared with older subjects, regardless of treatment.
Similarly, a previous study that evaluated onabotulinumtoxinA dose response in women with idiopathic OAB also found no age differences on multivariate analysis. 20 In contrast, a study of participants undergoing SNM reported that although both younger and older groups had a significant decrease in UUIE, greater improvement was noted in the younger cohort. 21 Variables noted in the current study that did influence mean UUIE reduction included the HUI-3 and UUIEs at baseline. Although there were no differences in HUI-3 scores at baseline, younger women with higher scores (reflecting better health status) had greater UUIE reduction, regardless of treatment a Age category and an age-category-by-treatment-group interaction term were included in the multivariable model irrespective of P value. For other predictors and interactions, terms were selected by backward selection subject to P < .1, as described in Materials and Methods. Coefficient estimates represent the mean daily reduction in UUIE episodes associated with a unit increase in the predictor; b Age <65 years, onabotulinumtoxinA, n ¼ 100, and neuromodulation, n ¼ 91. Age ! 65 years, onabotulinumtoxinA, n ¼ 90, and neuromodulation, n ¼ 83; c HUI-3 baseline SD in our study population. Komesu et al. Effect of age on refractory UUI treatment outcomes. Am J Obstet Gynecol 2018.
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modality. Higher baseline UUIEs also predicted greater UUIE reduction irrespective of age or treatment modality, an effect also noted in a trial of anticholinergic therapy vs 100 U of onabotulinumtoxinA for UUI. 5 This finding may reassure older women contemplating refractory UUI treatment that UUIE improves following either onabotulinumtoxinA or SNM despite relatively high baseline levels.
Diary outcomes also included evaluation of !75% UUIE reduction over 6 months. A significantly higher proportion of younger women, compared with older women, treated with onabotulinumtoxinA experienced !75% reduction. This age effect was not seen with SNM, although a previous SNM study did note cure rates (defined as no leakage episodes) that were higher in younger patients compared with older patients (65% vs 37%, P < .05). 21 To provide additional clinical perspective regarding attainment of !75% UUIE reduction, following SNM 26 of 88 women <65 years (29.5%) achieved this reduction compared with 17 of 78 women !65 years (21.8%). In contrast, following onobotulinumtoxinA 52 of 93 women <65 years (55.9%) achieved this reduction compared with 29 of 85 women !65 years (34.1%). Very few other data exist with regard to refractory UUI cure rates between older and younger women, but in general cure rates may be less in older women.
Regardless of age, women with degenerative disc disease treated with onabotulinumtoxinA therapy had reduced odds of attaining !75% reduction in UUIE. In theory, degenerative disc disease, especially with disc prolapse, could affect bladder function. 22, 23 Interestingly, a prior study evaluating factors associated with the use of a percutaneous nerve evaluation results in SNM found that prior intervertebral disc surgery was associated with 3.7 times higher odds of a successful test.
24
Perhaps women with self-reported, ongoing disc disease have more afferent/efferent sacral irritation that interferes with the peripheral effect of onabotulinumtoxinA, an effect not seen in SNM.
Because degenerative disc disease is a variable included in the FCI, the potential for colinearity between disc disease and FCI existed in our current analysis. A multivariable analysis was performed including an FCI score rather than disc disease as a predictor of !75% UUIE reduction. The total FCI score did not predict !75% UUIE reduction in this model (onabotulinumtoxinA; aOR, 0.86, 95% CI, 0.73e1.02; SNM aOR, 0.99, 95% CI, 0.83e1.18), confirming the importance of disc disease independently decreasing the effectiveness of onabotulinumtoxinA.
Other predictors of !75% reduction in UUIE included baseline IIQ and Sandvik scores. Greater UUI severity reflected in baseline IIQ and Sandvik scores were negative predictors of !75% reduction. IIQ was predictive only in onabotulinumtoxinA patients and higher Sandvik severity scores were predictive for both treatments.
With regard to quality-of-life outcomes, there were few differences in treatment response based on the majority of study questionnaires comparing younger and older women. Both age groups met the questionnaires' minimally important differences in improvement. Age differences were present only for OABq-SF symptom and A multivariable logistic regression model was used for analysis. Age category and an age-category-by-treatment-group interaction term were included in the multivariable model irrespective of P value. For other predictors and interactions, terms were selected by backward selection subject to P < 0.1, as described in Materials and Methods. Odds ratios represent the increased odds of a !75% reduction in UUI episodes associated with a unit increase in the predictor.
CI, confidence interval; IIQ, Incontinence Impact Questionnaire; UUIE, urgency urinary incontinence episode. Komesu et al. Effect of age on refractory UUI treatment outcomes. Am J Obstet Gynecol 2018.
Original Research GYNECOLOGY ajog.org OAB-SATq and LSA scores after treatment. Mean OABq-SF symptom bother score improvements were statistically better in the younger age group; however, the clinical significance of this difference is unclear because it did not meet the minimally important difference established for the OAB questionnaire. 19 Paradoxically, LSA scores showed less improvement in younger women compared with older women treated with onabotulinmutoxinA. This relationship between onabotulinumtoxinA and LSA did not seem to affect younger women's satisfaction scores with botulinum toxin treatment. OAB-SATq convenience and endorsement domains were higher in younger women treated with onabotulinumtoxinA. Perhaps diminished LSA (reflecting diminished mobility) was outweighed by the other benefits of onabotulinumtoxinA, resulting in higher treatment satisfaction in younger women.
Treatment-related AEs included UTIs, the need for clean intermittent selfcatheterization (CISC), and revision/ removal of SNM-associated devices. As noted in the study's prior publication, investigators used the 200 U dose of onabotulinumtoxinA (compared with 100 U) because data suggested that 200 U provided optimal durability for refractory UUI treatment. 7 Despite this higher dosage, UTIs and CISC occurrence were lower in the current study population as a whole than reported in other studies using the 200 U dosage. 7 Additionally, as reported in our previous ROSETTA publication, 7 UTIs were more common following onabotulinumtoxinA compared with SNM (35% vs 11% overall). This study indicates that women !65 years were more commonly treated for a UTI than women <65 years and that the same trend held true for recurrent UTIs (!2 UTIs over 6 months). UTIs in older women in ROSETTA, like women in the general population, increased with age. Ten percent of community-dwelling women report having had a UTI within a year, 25 with numbers increasing to 25% of women >85 years and 34% of women >95 years. 26 The nearly 2-fold increase in UTIs in older women in this study did not seem to affect OAB-SAT adverse event scores, in which no differences were found based on age groups. Whether UTI occurrence affected age differences in OAB-SAT endorsement or convenience remains unclear.
CISC was performed at some point within the first 6 months of onabotulinumtoxinA treatment in approximately 18e23% of patients, with no differences found between age groups. This differs from the report by Miotla et al, 27 who found elevated postvoid residuals and higher CISC occurrence in patients older than 68 years. SNM removal/revisions were uncommon, occurring in less than 5% of patients, and no differences were found between the age groups.
In conclusion, this is the largest prospective study comparing outcomes and AEs in older and younger women undergoing onabotulinumtoxinA or SNM for the treatment of refractory UUI. The study design allowed robust comparison of outcomes by age groups which, on average, differed by nearly 20 years. Study outcomes based on bladder diary and validated questionnaires permitted the evaluation of the patient experience from several important dimensions including UUI episodes, changes in symptom specific quality of life, patient endorsement, and AEs.
Weaknesses include the possibility that medically frail, cognitively impaired, and institutionalized women were underrepresented, given the rigorous data acquisition and follow-up required of trial participants.
In summary, both older and younger women with refractory UUI responded positively to both treatments. There were differences between age groups in UTIs and certain UUI diary parameters and questionnaire domains. Further followup is required to weigh longer-term benefits, including cost-effectiveness, vs adverse consequences of these refractory UUI treatments. n APPENDIX Quality-of-life outcomes and procedure-related adverse events 
